Prostate Cancer
Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation.
June 5, 2024
Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer.
June 4, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
June 3, 2024
In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
May 31, 2024